Clinical Trials Information
At Eastern Institute of Medical Sciences, our commitment is to helping to discover and develop innovative medicines to fight cancer. We are passionate about providing a broad range of new remedies and practical solutions that change the way patients handle cancer.
Eastern Institute of Medical Sciences is committed to bringing you new and innovative investigational cancer treatment options. One way we do this is by participating in cancer research trials and studies. As part of our mission to eliminate cancer, Eastern Institute of Medical Sciences will conduct clinical trials to test new treatments and techniques in patients for both common and rare cancers in an effort to find better ways to prevent, detect, diagnose, and cure diseases. Clinical Trials allow doctors to find out if new approaches are safe, and what benefits and risks are associated with them.
Our Open Trials
-Relapsed or Refractory Multiple Myeloma
A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide, Bortezomib and Low-Dose Dexamethasone versus Bortezomib and Low-Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma. Clinicaltrial.gov # NCT01734928
-Red Blood Cell Transfusion-dependent Anemia and Thrombocytopenia Due to IPSS Lower-risk Myelodysplastic Syndromes
A Phase 3, Multicenter, Randomized, Double-blind Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in Subjects With Red Blood Cell Transfusion-dependent Anemia and Thrombocytopenia Due to IPSS Lower-risk Myelodysplastic Syndromes. Clinicaltrial.gov # NCT01566695
-Iron Deficiency Anemia in a Clinical Setting
A Multi-Center, Randomized, Open Label Trial to Evaluate the Utility of Serum Hepcidin Levels to Predict Response to Oral or IV Iron and Compare the Safety, Effect on Quality of Life, and Resource Utilization of Injectafer vs. Intravenous Iron Standard of Care for the Treatment of Iron Deficiency Anemia (IDA) in an Infusion Center Setting. Clinicaltrial.gov # NCT01950247
-Previously Treated Chronic Phase Chronic Myelogenous Leukemia (CML)
A Non-Interventional Study of Bosutinib in Patients with Previously Treated Chronic Phase Chronic Myelogenous Leukemia (CML)
For more information regarding these clinical trials, please contact one of our Oncology Information Specialists at 252.321.1803. We are available Monday through Friday to discuss treatment options offered at Eastern Institute of Medical Sciences.
Or, visit clinicaltrials.gov and type in the trials NCT# found at the end of each trial’s description.